PitchBook：2026年 Q1生物制药工具领域风险投资趋势报告（英文版）（16页）.pdf

1、EMERGING TECH RESEARCHPharma Biotools VC TrendsVC activity across the pharma biotools ecosystem Q12026REPORT PREVIEWThe full report is available through the PitchBook Platform.CONFIDENTIAL.NOT FOR REDISTRIBUTION.Q1 2026 PHARMA BIOTOOLS VC TRENDS2ContentsInstitutional Research GroupBen Zercher Senior

2、 Research Analyst,Biotech&Pharma Caleb Wilkins Data APublished on June 3,2026Pharma biotools landscape 3Quarterly analysis 4Key takeaways 4Vertical overview 4VC activity 6Segment-level and regional trends 8AI themes 10Other notable events 11Conclusions 11Pharma biotools VC deal summary 34References

3、35CONFIDENTIAL.NOT FOR REDISTRIBUTION.Q1 2026 PHARMA BIOTOOLS VC TRENDS3Pharma biotoolslandscape For the complete pharma biotools taxonomy and company list,click here to see the market map on the PitchBook Platform.In silico discoveryDigital R&D&clinical infrastructure Engineered biologyPlatforms&re

4、agentsInstruments&capital equipment ServicesCONFIDENTIAL.NOT FOR REDISTRIBUTION.Q1 2026 PHARMA BIOTOOLS VC TRENDS4Quarterly analysisKey takeaways Pharma biotools companies raised$1.1 billion of VC funding across 122 deals in Q1 2026,maintaining the near-record deal count pace set in 2025.While deal

5、value moderated from the prior two quarters,strong Q1 2026 activity still drove 31%growth in TTM deal value.To better track funding activity,we introduce an enhanced segmentation framework that groups companies by product category,enabling more consistent valuation comparisons and trend analysis.Q1

6、capital favored platforms&reagents and services,but asset-light software models continued to command investor attention,particularly in drug discovery.Regional market preferences are diverging.Asian markets favored capital-intensive infrastructure and services,while North American and European marke